Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 31 Triple Negative Breast Neoplasms 19 Neoplasm Metastasis 5 Urinary Bladder Neoplasms 4 Carcinoma, Transitional Cell 4 Carcinoma, Non-Small-Cell Lung 4 Brain Neoplasms 4 Salivary Gland Neoplasms 2 Ovarian Neoplasms 2 Lung Neoplasms 2 Glioblastoma 2 Colorectal Neoplasms 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Mouth Neoplasms 1 Meningeal Carcinomatosis 1 Lung Diseases 1 Localized Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

eribulin 3 Vinorelbine 2 Paclitaxel 2 Epirubicin 2 Doxorubicin 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 liposomal doxorubicin 1 camrelizumab 1 anlotinib 1 Taxes 1 Precision Medicine 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-negative Breast Cancer × sacituzumab govitecan × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡